CoChat

Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes

Open access
Ehx, Grégory, Larouche, Jean-David, Durette, Chantal, Laverdure, Jean-Philippe, Hesnard, Leslie, Vincent, Krystel, Hardy, Marie-Pierre, Thériault, Catherine, Rulleau, Caroline, Lanoix, Joël, Bonneil, Eric, Feghaly, Albert, Apavaloaei, Anca, Noronha, Nandita, Laumont, Céline M., Delisle, Jean-Sébastien, Vago, Luca, Hébert, Josée, Sauvageau, Guy, Lemieux, Sébastien, Thibault, Pierre, Perreault, Claude · 2021 · Immunity
Cited by 122

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Acute myeloid leukemia (AML) has not benefited from innovative immunotherapies, mainly because of the lack of actionable immune targets. Using an original proteogenomic approach, we analyzed the major histocompatibility complex class I (MHC class I)-associated immunopeptidome of 19 primary AML samples and identified 58 tumor-specific antigens (TSAs). These TSAs bore no mutations and derived mainly (86%) from supposedly non-coding genomic regions. Two AML-specific aberrations were instrumental in the biogenesis of TSAs, intron retention, and epigenetic changes. Indeed, 48% of TSAs resulted from intron retention and translation, and their RNA expression correlated with mutations of epigenetic modifiers (e.g., DNMT3A). AML TSA-coding transcripts were highly shared among patients and were expressed in both blasts and leukemic stem cells. In AML patients, the predicted number of TSAs correlated with spontaneous expansion of cognate T cell receptor clonotypes, accumulation of activated cytotoxic T cells, immunoediting, and improved survival. These TSAs represent attractive targets for AML immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.immuni.2021.03.001

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 122

Metadata

Authors
Ehx, G., Larouche, J.-D., Durette, C., Laverdure, J.-P., Hesnard, L., Vincent, K., Hardy, M.-P., Thériault, C., Rulleau, C., Lanoix, J., Bonneil, E., Feghaly, A., Apavaloaei, A., Noronha, N., Laumont, C. M., Delisle, J.-S., Vago, L., Hébert, J., Sauvageau, G., Lemieux, S., Thibault, P., & Perreault, C.
Venue
Immunity
Publisher
Elsevier BV
Published
2021-04
Volume
54
Issue
4
Pages
737-752.e10
ISSN
1074-7613 (ISSN-L)
OpenAlex
W3138875598
Cited by
122
References
13
FWCI
6.40
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes. https://app.cochat.ai/papers/10.1016/j.immuni.2021.03.001
The paper
Ehx, G., Larouche, J.-D., Durette, C., Laverdure, J.-P., Hesnard, L., Vincent, K., Hardy, M.-P., Thériault, C., Rulleau, C., Lanoix, J., Bonneil, E., Feghaly, A., Apavaloaei, A., Noronha, N., Laumont, C. M., Delisle, J.-S., Vago, L., Hébert, J., Sauvageau, G., . . . Perreault, C. (2021). Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes. Immunity. https://doi.org/10.1016/j.immuni.2021.03.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.